Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

PURPOSE: Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell–directing activity, binds to each recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Keunchil, Haura, Eric B., Leighl, Natasha B., Mitchell, Paul, Shu, Catherine A., Girard, Nicolas, Viteri, Santiago, Han, Ji-Youn, Kim, Sang-We, Lee, Chee Khoon, Sabari, Joshua K., Spira, Alexander I., Yang, Tsung-Ying, Kim, Dong-Wan, Lee, Ki Hyeong, Sanborn, Rachel E., Trigo, José, Goto, Koichi, Lee, Jong-Seok, Yang, James Chih-Hsin, Govindan, Ramaswamy, Bauml, Joshua M., Garrido, Pilar, Krebs, Matthew G., Reckamp, Karen L., Xie, John, Curtin, Joshua C., Haddish-Berhane, Nahor, Roshak, Amy, Millington, Dawn, Lorenzini, Patricia, Thayu, Meena, Knoblauch, Roland E., Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791812/
https://www.ncbi.nlm.nih.gov/pubmed/34339292
http://dx.doi.org/10.1200/JCO.21.00662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791812/
https://www.ncbi.nlm.nih.gov/pubmed/34339292
http://dx.doi.org/10.1200/JCO.21.00662

Ejemplares similares